Global Pharma, Biotech and Diagnostics Asset Purchase Partnering Terms and Agreements Directory 2018 - ResearchAndMarkets.com
The "Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018" report has been added to ResearchAndMarkets.com's offering.
The "Global
Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and
Diagnostics 2012 to 2018" report has been added to ResearchAndMarkets.com's
offering.
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics
2012-2018 report provides a detailed understanding and analysis of how
and why companies enter business, product, technology and royalty assets.
The report provides a detailed understanding and analysis of how and why
companies enter business, product, technology and royalty assets.
The focus of the report is on partnerships for business, product,
technology and royalty assets where partners have entered an agreement
to dispose of or acquire said assets.
Companies may seek to dispose of an asset simply because it is surplus
to requirements. Or it may seek to dispose of assets in order to raise
funds to invest in others parts of its business. Or it may be due to a
regulatory requirement to dispose of certain business or product assets
as a result of a pending business merger in order to meet competition
regulations.
The report provides access to asset purchase deal payment terms as
announced between the parties. This data provides useful insight into
the payment and other deal terms.
The report focuses on four primary types of asset available for purchase:
Business assets - the most common asset exchanging hands. Business
assets are in the form of a business unit or subsidiary of a parent
company. Common assets include territorial businesses or non-core
businesses such as an OTC or diagnostics business, separate from the
core business operations
Product assets - in the form of marketed product, clinical phase
development compound, or drug delivery-compound combination. These
assets are commonly available as a result of a merger or change in
direction of the selling company. The buyer acquires the asset for
global or territorial exploitation. It is often the case that the
acquiring company is normally a competitor to the seller, but in this
situation the trade is of mutual benefit
Royalty assets - where a specialist investment company acquires the
rights to future royalty payments in return for payment of a lump sum
payment to the licensor for the product
Technology asset - where a buyer is acquiring a technology platform,
research program, patent portfolio or other intellectual property asset.
The acquisition is often due to the technology being surplus to a
sellers interests, but may also be as a consequence of a sale of assets
in advance of the seller entering liquidation
Understanding the flexibility of a prospective partner's negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered and rights transferred - contract documents provide this
insight where press releases and databases do not.
This report contains a comprehensive listing of over 1,000 asset
purchase deals announced since 2012 as recorded in the Current
Agreements deals and alliances database, including financial terms where
available, plus links to online copies of actual asset purchase contract
documents as submitted to the Securities Exchange Commission by
companies and their partners.
Contract documents provide the answers to numerous questions about a
prospective partner's flexibility on a wide range of important issues,
many of which will have a significant impact on each party's ability to
derive value from the deal.
The initial chapters of this report provide an orientation of Asset
Purchase dealmaking and business activities. Chapter 1 provides an
introduction to the report, whilst chapter 2 provides an overview and
analysis of the trends in Asset Purchase as well as a discussion on the
merits of the type of deal.
Chapter 3 provides an overview of the structure of Asset Purchase deals.
The chapter includes numerous case studies to enable understanding of
both pure Asset Purchase deals and multicomponent deals where Asset
Purchase forms a part.
Chapter 4 provides a review of the leading Asset Purchase deals since
2012. Deals are listed by headline value. Where the deal has an
agreement contract published at the SEC a link provides online access to
the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 most active
Asset Purchase dealmaker companies. Each deal title links via Current
Agreements deals and alliances database to an online version of the full
deal record, and where available, the actual contract document,
providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of Asset Purchase
deals organized by company A-Z, therapy, technology and industry type
signed and announced since 2012 where a contract document is available.
Contract documents provide an in depth insight into the actual deal
terms agreed between the parties with respect to the Asset Purchase deal.
The appendices to the report includes a comprehensive listing of all
Asset Purchase deals announced since 2012. Each listing is organized as
an appendix by company A-Z, stage of development at signing, therapeutic
area and industry type. Each deal title links via hyperlink to an online
version of the deal record including, where available, the actual
contract document.
The report includes deals announced by hundreds of life science
companies including big pharma such as Abbott, Abbvie, Actavis, Amgen,
Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai,
Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan,
Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant,
amongst many others.
The report also includes numerous table and figures that illustrate the
trends and activities in Asset Purchase dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker
needs to know about Asset Purchase alliances.
Key benefits
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2012-2018
provides the reader with the following
Key benefits:
- In-depth understanding of asset purchase deal trends since 2012
-
Analysis of the structure of asset purchase agreements with numerous
real life case studies -
Comprehensive access to over 1,000 actual asset purchase deals entered
into by the world's biopharma companies -
Detailed access to actual asset purchase deals entered into by leading
biopharma companies -
Insight into the terms included in a asset purchase agreement,
together with real world clause examples - Understand the key deal terms companies have agreed in previous deals
-
Undertake due diligence to assess suitability of your proposed deal
terms for partner companies
Report scope
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2012-2018
is intended to provide the reader with an in-depth understanding of the
asset purchase trends and structure of deals entered into by leading
biopharma companies worldwide.
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2012-2018
includes:
-
Trends in asset purchase dealmaking in the biopharma industry since
2012 - Analysis of asset purchase deal structure
- Case studies of real-life asset purchase deals
- Access to over 1,000 asset purchase deal records
- The leading asset purchase deals by value since 2012
- Most active asset purchase dealmakers since 2012
- The leading asset purchase partnering resources
In Global Asset Purchase Deals in Pharma, Biotech and Diagnostics
2012-2018, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
For more information about this report visit https://www.researchandmarkets.com/research/42b2kl/global_asset?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190327005711/en/